- Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clark, J.W., Eder, J.P., Ryan, D., Lathia, C., Lenz, H.J. Clin. Cancer Res. (2005)